Let’s Check the Math on Health Subsidies

By KIM BELLARD It’s December 3, and, to no one’s surprise, Congress still has not acted on extending the expanded health care premium tax credits for ACA. To Congress, the subsidies don’t expire until the end of the year, so they figure they have until at least then to act, or maybe sometime after that,…

Read More

Higher Drug Prices, No Tariffs: U.K. Trade Pact Shows How Trump Is Coaxing Countries to Pay More for Meds

The U.K. cost-effectiveness standard for drugs will increase by 25% in exchange for zero tariffs on the country’s pharmaceutical exports. The new trade agreement’s parameters could shape deals the Trump administration is pursuing with other countries. The post Higher Drug Prices, No Tariffs: U.K. Trade Pact Shows How Trump Is Coaxing Countries to Pay More…

Read More

Potential “Chilling Effects” of Public Charge and Other Immigration Policies on Medicaid and CHIP Enrollment

This issue brief reviews the Department of Homeland Security (DHS) proposed rule that would rescind 2022 Biden-era public charge determination regulations. The proposed public charge changes along with other Trump administration policy changes will likely lead to decreased participation in public programs, including Medicaid, among a broad group of immigrant families, including citizen children in…

Read More

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon, Kathryn Spurrier, Katharine Batt and David Wei. The abstract is below. ObjectiveTyrosine kinase inhibitors (TKIs) have transformed the prognosis of chronic myeloid leukemia (CML) into a manageable…

Read More